Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy Xyphos shareholders to receive up to $665 million in structured, milestone-based acquisition
The STADA Group, a global manufacturer of high-quality generic drugs and consumer healthcare products, continues its growth trajectory in Europe. The company, headquartered in Germany, announced today that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.
GSK to receive upfront payment of approximately EUR301 million (£259m) and milestone payments for a total consideration of up to EUR955 million (£822m)
Acino and Takeda Pharmaceuticals announced today that they have signed an agreement for Acino to acquire parts of Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine. The acquisition will further strengthen Acino’s position in these important regions.
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the completion of an $80 million Series B financing.